文献速递自身炎症与 IgG4 相关病

吡林相关中性粒细胞性皮肤病患者的表型分析与治疗观察

Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该开放标签先导研究纳入3例PAAND患者评估阿那白滞素疗效,结果显示1例治疗失败、2例部分缓解,皮肤病变无明显改善,未扩大治疗队列。回顾性收集另外8例患者资料,发现PAAND存在显性和隐性遗传及可变外显率,并常见此前未认识的胃肠道受累。

要点

  • 阿那白滞素在PAAND中未优于靶向TNF-α的生物制剂。
  • 阿那白滞素对PAAND突出皮肤表现无明显效果。
  • PAAND可呈显性或隐性遗传且外显率可变,常见胃肠道受累。

核心结论

  • 在研究者经验中,阿那白滞素虽看似安全,但在PAAND中并不优于靶向TNF-α的生物制剂,尽管有证据直接提示IL-1β信号失调。

研究设计与样本

  • 开放标签先导研究,初步阶段招募3例PAAND患者接受阿那白滞素治疗,若反应有利则计划扩大治疗队列。
  • 监测急性期反应物和血浆细胞因子水平,基线和第12周皮肤活检染色相关细胞因子。
  • 回顾性收集另外8例PAAND患者的治疗反应临床数据。

主要发现

  • 初步阶段3例患者(P1-P3)中1例治疗失败、2例部分缓解,1例选择继续阿那白滞素,另1例倾向阿达木单抗。
  • 虽观察到部分全身性反应,但阿那白滞素对突出皮肤表现无明显效果,反映为皮损局部炎症细胞因子表达残留。
  • 这些观察不支持进一步扩大治疗队列。
  • 回顾性收集的另外8例患者(P4-P11)资料显示PAAND存在显性和隐性遗传及可变外显率,并常见此前未认识的胃肠道受累。

临床怎么用

  • 对于PAAND患者,阿那白滞素虽安全但未显示优于靶向TNF-α的生物制剂,临床决策需综合评估。
  • PAAND患者应关注胃肠道受累,并注意显性和隐性遗传及可变外显率。

局限性

  • 先导研究初步阶段仅招募3例患者,因反应不佳未扩大队列,样本量小。
  • 额外8例患者的临床数据为回顾性收集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2016 specific heterozygous gain-of-function mutations in the Mediterranean fever gene MEFV were reported as causal for a distinct autoinflammatory disease coined pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). We sought to provide an extended report on clinical manifestations in PAAND patients to date and evaluate the efficacy and safety of treatment with the IL-1-blocking agent anakinra. METHODS: We undertook an open-label pilot study with anakinra. Three patients were recruited in a preliminary phase of the study with the intention to expand the treatment cohort in case of a favourable response. Acute-phase reactants and plasma cytokine levels were monitored throughout. Skin biopsies at baseline and at week 12 were stained for relevant cytokines. Available clinical data on treatment responses were retrospectively collected on additional patients. RESULTS: The three patients from the preliminary phase of the study [patients 1-3 (P1-P3)] demonstrated one failed and two partial treatment responses, where one patient opted to continue treatment with anakinra and the other favoured adalimumab. While a partial systemic response was observed, there was no appreciable effect of anakinra on the prominent cutaneous manifestations, reflected in residual local inflammatory cytokine expression in lesional skin. These observations did not warrant further expansion of the treatment cohort. Clinical data was retrospectively collected on an additional eight patients (P4-P11), highlighting both dominant and recessive inheritance with variable penetrance in PAAND and common gastrointestinal involvement that was not previously appreciated. CONCLUSION: In our experience, while anakinra appears safe, it was not superior to biologicals targeting TNF-α in PAAND despite evidence directly implicating dysregulated IL-1β signalling.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Van Nieuwenhove E, De Langhe E, Dooley J, et al. Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment. Rheumatology (Oxford). 2021. PMID: 33693560. doi:10.1093/rheumatology/keab221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。